Patents by Inventor Donald J. P. Pinto

Donald J. P. Pinto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
    Patent number: 9975891
    Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: May 22, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventor: Donald J. P. Pinto
  • Dihydropyridone P1 as factor XIa inhibitors
    Patent number: 9951071
    Abstract: The present invention provides compounds of Formula (V): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: April 24, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wu Yang, James R. Corte, Paul J. Gilligan, Donald J. P. Pinto, William R. Ewing, Andrew K. Dilger, Yufeng Wang, Tianan Fang, Kumar B. Pabbisetty, Leon M. Smith, II
  • Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
    Patent number: 9944625
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: April 17, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael J. Orwat, Donald J. P. Pinto, Leon M. Smith, II, Shefali Srivastava
  • Macrocycles as factor XIa inhibitors
    Patent number: 9902742
    Abstract: The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: February 27, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, James R. Corte, Paul J. Gilligan, Tianan Fang, Leon M. Smith, II, Yufeng Wang, Wu Yang, William R. Ewing
  • MACROCYCLES AS FACTOR XIA INHIBITORS
    Publication number: 20180022753
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 25, 2018
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J.P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES
    Publication number: 20170342071
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: August 18, 2017
    Publication date: November 30, 2017
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • Macrocycles as factor XIa inhibitors
    Patent number: 9802939
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: October 31, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J. P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS
    Publication number: 20170305880
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Application
    Filed: July 7, 2017
    Publication date: October 26, 2017
    Inventors: Michael J. Orwat, Donald J.P. Pinto, Leon M. Smith, II, James R. Corte, Shefali Srivastava
  • Macrocycles with aromatic P2? groups as factor xia inhibitors
    Patent number: 9777001
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: October 3, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J. P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
    Patent number: 9738655
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: August 22, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, Charles G. Clarke, Leon M. Smith, II, Michael J. Orwat, Yoon Jeon, James R. Corte
  • Substituted 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as factor XIa inhibitors
    Patent number: 9725435
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: August 8, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael J. Orwat, Donald J. P. Pinto, Leon M. Smith, II, James R. Corte, Shefali Srivastava
  • NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS
    Publication number: 20170158712
    Abstract: The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: February 21, 2017
    Publication date: June 8, 2017
    Inventors: Donald J. P. Pinto, James R. Corte, Paul J. Gilligan, Tianan Fang, Leon M. Smith, II, Yufeng Wang, Wu Yang, William R. Ewing
  • MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS
    Publication number: 20170096429
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: January 30, 2015
    Publication date: April 6, 2017
    Applicant: Bristol-Myers Squibb Company
    Inventors: James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • Macrocycles as factor XIa inhibitors
    Patent number: 9611274
    Abstract: The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: April 4, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, James R. Corte, Paul J. Gilligan, Tianan Fang, Leon M. Smith, II, Yufeng Wang, Wu Yang, William R. Ewing
  • SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS
    Publication number: 20170073330
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Application
    Filed: November 28, 2016
    Publication date: March 16, 2017
    Inventors: Michael J. Orwat, Donald J.P. Pinto, Leon M. Smith, II, Shefali Srivastava
  • MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES
    Publication number: 20170057961
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: January 30, 2015
    Publication date: March 2, 2017
    Applicant: Bristol-Myers Squibb Company
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
    Publication number: 20170050964
    Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Application
    Filed: November 7, 2016
    Publication date: February 23, 2017
    Inventors: Donald J.P. Pinto, Mimi L. Quan, Michael J. Orwat, Yun-Long Li, Wei Han, Jennifer X. Qiao, Patrick Y.S. Lam, Stephanie L. Koch
  • MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS
    Publication number: 20170002006
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: January 30, 2015
    Publication date: January 5, 2017
    Inventors: James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • PYRIMIDINONES AS FACTOR XIA INHIBITORS
    Publication number: 20160368923
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 27, 2016
    Publication date: December 22, 2016
    Inventors: Andrew K. Dilger, James R. Corte, lndawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith II
  • DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS
    Publication number: 20160340360
    Abstract: The present invention provides compounds of Formula (V): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 8, 2016
    Publication date: November 24, 2016
    Inventors: Wu Yang, James R. Corte, Paul J. Gilligan, Donald J.P. Pinto, William R. Ewing, Andrew K. Dilger, Yufeng Wang, Tianan Fang, Kumar B. Pabbisetty, Leon M. Smith, II